Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM).

Tissue-based genomic profiling is still considered as the gold standard 1 Esagian S.M. Grigoriadou G.I. Nikas I.P. et al. Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. J Cancer Res Clin Oncol. 2020; 146: 2051-2066 Crossref PubMed Scopus (42) Google Scholar to assist decision making for genomics-driven therapy in patients with advanced cancer. Nevertheless, it has several limitations including screening failures due to limited tissue availability, and inability to capture intratumor spatial and temporal heterogeneity, which may impair accurate treatment selection. Moreover, acquisition of tumor biopsy is challenging and could lead to adverse events not expected with simple blood withdrawal. 2 Recondo G. Mahjoubi L. Maillard A. et al. Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. NPJ Precis Oncol. 2020; 4: 27 Crossref PubMed Scopus (7) Google Scholar ,3 Prud’homme C. Deschamps F. Allorant A. et al. Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): what are the real risks?. Eur J Cancer. 2018; 103: 108-119 Abstract Full Text Full Text PDF PubMed Scopus (16) Google Scholar